ArticleBritish journal of cancer2011
Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.
Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients.The EPMA journal · 2026Review
- Article
- Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.The Prostate · 2023Article
- Pheochromocytoma: a changing perspective and current concepts.Therapeutic advances in endocrinology and metabolism · 2023Review
- Heterotopic pancreatic tissue masquerading as a neuroendocrine tumour.ANZ journal of surgery · 2022Article
- Review
- Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.Journal of clinical medicine · 2022Review
- Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors.Diagnostics (Basel, Switzerland) · 2020Article
- Article
- Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019Article
- PANCREATIC NEUROENDOCRINE TUMORS: SURGICAL RESECTION.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2019Review
- An unusual case of proton pump inhibitor induced hyperchromograninemia.Journal of community hospital internal medicine perspectives · 2019Article
- Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2018Article
- Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.Frontiers in endocrinology · 2018Article
- Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.Japanese journal of clinical oncology · 2017Article
- Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.Journal of gastroenterology · 2017Review
- Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Cancer science · 2014Article
- Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Journal of endocrinological investigation · 2014Article
- The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.PloS one · 2013Article
- Safety assessment of omeprazole use: a review.Sao Paulo medical journal = Revista paulista de medicinaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this prospective study was to examine whether discontinuation of proton pump inhibitors (PPIs) or replacement by H(2)-receptor antagonists (H2RA) resulted in a decrease of chromogranin A (CgA) levels in 196 patients with well-differentiated neuroendocrine tumours (NETs).
methodsPatients with an unexpectedly high CgA level not connected with NET disease discontinued PPIs, or used H2RA instead; 2 weeks later CgA level was measured again.
resultsIn all, 19 out of 196 (10%) patients showed unexpected elevated CgA levels, they all used PPI. In 11 out of 19 patients with no evidence of the disease, median CgA decreased from 390 μg l(-1) during PPI treatment to 56 μg l(-1) after discontinuation (P=0.003). In 8 out of 19 patients with stable disease, median CgA decreased from 618 to 318 μg l(-1) (P=0.012). In 12 out of 19 patients who ceased all acid inhibition, CgA levels decreased by 82%, while in the seven patients who replaced PPI by H2RA, CgA decreased by 77% (P=0.967).
conclusionProton pump inhibitor use causes falsely elevated CgA levels in patients with NET. We recommend to stop, or replace PPI by H2RA, to obtain a reliable CgA value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.